Clinical Efficacy and Immune Function of Andrographolide Sulfonate in Children with Mycoplasma Pneumoniae Pneumonia

• Published in: Clinical laboratory (Heidelberg) Vol. 69; no. 8
• Main Authors: Li, Jun, Hao, Heng-Rui, Feng, Su-Fang
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2023
• ISSN: 1433-6510
• DOI: 10.7754/Clin.Lab.2022.220339

To figure out the effect of andrographolide sulfonate on the clinical efficacy and immune function of children with mycoplasma pneumoniae pneumonia (MPP). From January 2019 to April 2021, a total of 102 children with MPP were selected as the research group. They were assigned into the control and the observation groups by random number table method, with 51 cases/group. The control group was given routine treatment, and the observation was given andrographolide sulfonate treatment. The therapeutic efficacy and improvement of clinical symptoms were compared between the two. The changes of immune function, pulmonary function, myocardial enzymology indexes, MCP-4, IL-1β, IFN-γ, and TNF-α were noticed in the groups before and after treatment. The presence of drug-related adverse reactions of patients was recorded during treatment. The total effective rate of treatment in the observation group was higher, and the time of fever reduction, pulmonary rales disappearance and cough disappearance time were all shorter vs. the control group (p < 0.05). Immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) in the observation group after treatment were higher, and monocyte chemoattractant protein 4 (MCP-4), interleukin-1β (IL-1β), interferon-γ (IFN- γ), and tumor necrosis factor-α (TNF-α) were reduced vs. the control group. The forced expiratory volume in the 1st second (FEV1) and the percentage of forced vital capacity occupied by the forced expiratory volume in the first second (FEV1/FVC) and peak expiratory flow (PEF) values were higher (p < 0.05), but aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) and isoenzyme (CK-MB) were reduced in the observation group after treatment vs. the control group (p < 0.05); No serious adverse reactions took place in the two during treatment. The treatment of andrographolide sulfonate in children with MPP can enhance the therapeutic effect, ameliorate the immune function and lung function of children, and reduce inflammation and myocardial enzymes.